Sunday, the U.S. Senate passed the landmark drug pricing bill. While the pharmaceutical industry favors the bill’s Medicare out-of-pocket cap for patients, the industry has also put up a major fight against Medicare pricing negotiations, in fact deeming them "price controls." The bill’s passage marked a loss for the industry, but analysts aren’t sure how much the legislation will actually cut drug prices. 

Pfizer is riding high on its COVID-19 windfall. And with all that money in the bank, the Big Pharma has been busy scouring the biopharma landscape for new assets and companies to bring into its fold. The latest in its buying spree is a $5.4 billion acquisition of Global Blood Therapeutics and its marketed sickle cell disease drug.

To learn more about the topics in this episode: 

The Top Line is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

See omnystudio.com/listener for privacy information.